| abstract |
The present invention provides novel 16-ene-C25-oxime and 16-ene-C-25-oxime ether analogs of 1alpha,25-dihydroxy vitamin D<SUB>3</SUB>, compositions comprising these compounds and methods of using these compounds as inhibitors of CYP24. In particular, the compound of Formula I are useful for treating diseases which benefit from a modulation of the levels of 1alpha,25-dihydroxy vitamin D<SUB>3</SUB>, for example, cell-proliferative disorders. |